Transcriptomic-Driven Drug Repurposing Reveals SP600125 as a Promising Drug Candidate for the Treatment of Glial-Mesenchymal Transition in Glioblastoma
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26199772 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Kirill V Odarenko und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, Russia. Hauptthemen laut MEDLINE: Glioblastoma, Drug Repositioning, Brain Neoplasms, Transcriptome. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 163 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian Science Foundation, Russian state-funded project for ICBFM SB RAS.
Abstract (Originalsprache)
Glioblastoma multiforme (GBM) is an aggressive brain cancer characterized by highly invasive growth driven by glial-mesenchymal transition (GMT). Given the urgent need for effective therapies targeting this process, we aimed to discover potential GMT inhibitors using transcriptomic-based repurposing applied to both approved and experimental drugs. Deep bioinformatic analysis of transcriptomic data from GBM patient tumors and GBM cell lines with mesenchymal phenotype using gene set variation analysis (GSVA), weighted gene co-expression network analysis (WGCNA), reconstruction of GMT-related gene association networks, gene set enrichment analysis (GSEA), and the search for correlation with transcriptomic profiles of known GMT markers, revealed a novel 31-gene GMT signature applicable as relevant input data for the connectivity map-based drug repurposing study. Using this gene signature, a number of small-molecule compounds were predicted as potent anti-GMT agents. Further ranking according to their blood–brain barrier permeability, as well as structural and transcriptomic similarities to known anti-GBM drugs, revealed SP600125, vemurafenib, FG-7142, dibenzoylmethane, and phensuximide as the most promising for GMT inhibition. In vitro validation showed that SP600125, which is most closely associated with GMT-related hub genes, effectively inhibited TGF-β1- and chemical hypoxia-induced GMT in U87 GBM cells by reducing morphological changes, migration, vasculogenic mimicry, and mesenchymal marker expression. These results clearly demonstrate the applicability of connectivity mapping as a powerful tool to accelerate the discovery of effective GMT-targeting therapies for GBM and significantly expand our understanding of the antitumor potential of SP600125.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, Russia.
ORCID-Profile: Kirill V Odarenko, Marina A Zenkova, Andrey V Markov
Förderung
- Russian Science Foundation
- Russian state-funded project for ICBFM SB RAS
Zitieren
APA
Odarenko, K. V., Zenkova, M. A., & Markov, A. V. (2025). Transcriptomic-Driven Drug Repurposing Reveals SP600125 as a Promising Drug Candidate for the Treatment of Glial-Mesenchymal Transition in Glioblastoma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26199772
Vancouver
Odarenko KV, Zenkova MA, Markov AV. Transcriptomic-Driven Drug Repurposing Reveals SP600125 as a Promising Drug Candidate for the Treatment of Glial-Mesenchymal Transition in Glioblastoma. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26199772
BibTeX
@article{Odarenko2025,
author = {Odarenko, Kirill V and Zenkova, Marina A and Markov, Andrey V},
title = {Transcriptomic-Driven Drug Repurposing Reveals SP600125 as a Promising Drug Candidate for the Treatment of Glial-Mesenchymal Transition in Glioblastoma},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26199772}
}
EUVIMED